These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33107641)

  • 1. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
    Zhang C; Wu Z; Li JW; Tan K; Yang W; Zhao H; Wang GQ
    J Med Virol; 2021 Mar; 93(3):1378-1386. PubMed ID: 33107641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
    Ferrara F; Granata G; Pelliccia C; La Porta R; Vitiello A
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1615-1618. PubMed ID: 32594204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-related fibrosis: insights into potential drug targets.
    Sgalla G; Comes A; Lerede M; Richeldi L
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1183-1195. PubMed ID: 34842488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Fibrosis Caused by Severe COVID-19 Infection: Discharge May Not Be The End of Treatment.
    Rumende CM
    Acta Med Indones; 2021 Apr; 53(2):141-142. PubMed ID: 34251340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
    Zou H; Li SQ
    Acta Pharmacol Sin; 2021 Aug; 42(8):1376-1378. PubMed ID: 33188277
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
    Hamidi SH; Kadamboor Veethil S; Hamidi SH
    Pharmacol Rep; 2021 Jun; 73(3):712-727. PubMed ID: 33880743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 8. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

  • 9. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors.
    P KM; Sivashanmugam K; Kandasamy M; Subbiah R; Ravikumar V
    Life Sci; 2021 Feb; 266():118883. PubMed ID: 33316266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insight from the first lung transplant of a COVID-19 patient.
    Chen XJ; Li K; Xu L; Yu YJ; Wu B; He YL; Zhao WE; Li D; Luan CX; Hu L; Wang J; Ding JJ; Yu YF; Li JX; Tan ZM; Liu XF; Wei D; Zhang ZH; Guo XJ; Su C; Hu ZB; Guo YS; Chen JY; Chen F
    Eur J Clin Invest; 2021 Jan; 51(1):e13443. PubMed ID: 33131070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.
    Al-Kuraishy HM; Batiha GE; Faidah H; Al-Gareeb AI; Saad HM; Simal-Gandara J
    Inflammopharmacology; 2022 Dec; 30(6):2017-2026. PubMed ID: 36044102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifibrotic therapy and progressive lung fibrosis].
    Fellrath JM
    Rev Med Suisse; 2020 Jun; 16(698):1256-1260. PubMed ID: 32558455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary fibrosis secondary to COVID-19: a narrative review.
    Tanni SE; Fabro AT; de Albuquerque A; Ferreira EVM; Verrastro CGY; Sawamura MVY; Ribeiro SM; Baldi BG
    Expert Rev Respir Med; 2021 Jun; 15(6):791-803. PubMed ID: 33902377
    [No Abstract]   [Full Text] [Related]  

  • 16. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis.
    Bahudhanapati H; Kass DJ
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):10-11. PubMed ID: 28665219
    [No Abstract]   [Full Text] [Related]  

  • 18. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
    Bari E; Ferrarotti I; Saracino L; Perteghella S; Torre ML; Richeldi L; Corsico AG
    Cells; 2021 May; 10(5):. PubMed ID: 34068958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.